비소세포폐암 치료제 시장 규모, 점유율 및 동향 분석 보고서 : 유형별, 치료법별, 유통 채널별, 지역별 및 부문별 전망(2026-2033년)

Non-small Cell Lung Cancer Therapeutics Market Summary

The global non-small cell lung cancer therapeutics market size was valued at USD 24.1 billion in 2025 and is projected to grow from USD 27.1 billion in 2026 to USD 63.5 billion by 2033, at a CAGR of 12.9% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 35.4% in 2025. NSCLC remains the most common form of lung cancer, accounting for nearly 85% of all lung cancer cases worldwide.

The treatment landscape has shifted from conventional chemotherapy toward targeted therapies and immune checkpoint inhibitors, supported by updated clinical guidelines and broader molecular profiling in routine practice. Earlier diagnosis through screening programs in selected countries is also increasing the number of patients receiving treatment at earlier disease stages. However, treatment costs, unequal access to molecular diagnostics, and differences in healthcare infrastructure across regions continue to affect therapy adoption. Ongoing clinical research and regulatory approvals are expanding treatment options and supporting sustained market development.

Global Non-small Cell Lung Cancer Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global non-small cell lung cancer therapeutics market report based on type, treatment, distribution channel, and region:

• Type Outlook (Revenue, USD Billion, 2021 - 2033)
• Squamous Cell Carcinoma
• Large Cell Carcinoma
• Adenocarcinoma
• Others
• Treatment Outlook (Revenue, USD Billion, 2021 - 2033)
• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Others
• Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
• Hospital Pharmacy
• Drug Store and Retail Pharmacy
• Online Pharmacy
• Regional Outlook (Revenue, USD Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Treatment
  • 1.2.3. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Non-small Cell Lung Cancer Therapeutics Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Non-small Cell Lung Cancer Therapeutics Market: Type Business Analysis

• 4.1. Type Market Share, 2025 & 2033
• 4.2. Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Billion)
• 4.4. Squamous Cell Carcinoma
  • 4.4.1. Squamous Cell Carcinoma Market, 2021 - 2033 (USD Billion)
• 4.5. Large Cell Carcinoma
  • 4.5.1. Large Cell Carcinoma Market, 2021 - 2033 (USD Billion)
• 4.6. Adenocarcinoma
  • 4.6.1. Adenocarcinoma Market, 2021 - 2033 (USD Billion)
• 4.7. Others
  • 4.7.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 5. Non-small Cell Lung Cancer Therapeutics Market: Treatment Business Analysis

• 5.1. Treatment Market Share, 2025 & 2033
• 5.2. Treatment Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2021 to 2033 (USD Billion)
• 5.4. Chemotherapy
  • 5.4.1. Chemotherapy Market, 2021 - 2033 (USD Billion)
• 5.5. Targeted Therapy
  • 5.5.1. Targeted Therapy Market, 2021 - 2033 (USD Billion)
• 5.6. Immunotherapy
  • 5.6.1. Immunotherapy Market, 2021 - 2033 (USD Billion)
• 5.7. Others
  • 5.7.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 6. Non-small Cell Lung Cancer Therapeutics Market: Distribution Channel Business Analysis

• 6.1. Distribution Channel Market Share, 2025 & 2033
• 6.2. Distribution Channel Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Billion)
• 6.4. Hospital Pharmacy
  • 6.4.1. Hospital Pharmacy Market, 2021 - 2033 (USD Billion)
• 6.5. Drug Store and Retail Pharmacy
  • 6.5.1. Drug Store and Retail Pharmacy Market, 2021 - 2033 (USD Billion)
• 6.6. Online Pharmacy
  • 6.6.1. Online Pharmacy Market, 2021 - 2033 (USD Billion)

Chapter 7. Non-small Cell Lung Cancer Therapeutics Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2025 & 2033
• 7.2. Regional Market Dashboard
• 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 7.4. North America
  • 7.4.1. North America Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Billion)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Target Disease Prevalence
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Reimbursement Framework
    • 7.4.2.5. U.S. Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Target Disease Prevalence
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Reimbursement Framework
    • 7.4.3.5. Canada Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Target Disease Prevalence
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Reimbursement Framework
    • 7.4.4.5. Mexico Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 7.5. Europe
  • 7.5.1. Europe Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Target Disease Prevalence
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement Framework
    • 7.5.2.5. UK Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Target Disease Prevalence
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement Framework
    • 7.5.3.5. Germany Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Target Disease Prevalence
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. Reimbursement Framework
    • 7.5.4.5. France Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Target Disease Prevalence
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Reimbursement Framework
    • 7.5.5.5. Italy Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Target Disease Prevalence
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Reimbursement Framework
    • 7.5.6.5. Spain Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.5.7. Denmark
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Target Disease Prevalence
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Reimbursement Framework
    • 7.5.7.5. Denmark Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.5.8. Sweden
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Target Disease Prevalence
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Reimbursement Framework
    • 7.5.8.5. Sweden Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.5.9. Norway
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Target Disease Prevalence
    • 7.5.9.3. Regulatory Framework
    • 7.5.9.4. Reimbursement Framework
    • 7.5.9.5. Norway Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Target Disease Prevalence
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement Framework
    • 7.6.2.5. Japan Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Target Disease Prevalence
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement Framework
    • 7.6.3.5. China Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Target Disease Prevalence
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement Framework
    • 7.6.4.5. India Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.6.5. Australia
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Target Disease Prevalence
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement Framework
    • 7.6.5.5. Australia Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.6.6. South Korea
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Target Disease Prevalence
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Reimbursement Framework
    • 7.6.6.5. South Korea Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Target Disease Prevalence
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Reimbursement Framework
    • 7.6.7.5. Thailand Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 7.7. Latin America
  • 7.7.1. Latin America Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Target Disease Prevalence
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Reimbursement Framework
    • 7.7.2.5. Brazil Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Target Disease Prevalence
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Reimbursement Framework
    • 7.7.3.5. Argentina Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 7.8. Middle East and Africa
  • 7.8.1. Middle East and Africa Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Target Disease Prevalence
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Reimbursement Framework
    • 7.8.2.5. South Africa Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Target Disease Prevalence
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Reimbursement Framework
    • 7.8.3.5. Saudi Arabia Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Target Disease Prevalence
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. Reimbursement Framework
    • 7.8.4.5. UAE Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Target Disease Prevalence
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Reimbursement Framework
    • 7.8.5.5. Kuwait Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. AstraZeneca PLC
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. Merck & Co., Inc.
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. F. Hoffmann-La Roche Ltd.
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Bristol Myers Squibb.
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Johnson & Johnson
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. Pfizer Inc.
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Novartis AG
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. Eli Lilly and Company
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. GSK plc
    • 8.5.9.1. Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. Boehringer Ingelheim
    • 8.5.10.1. Overview
    • 8.5.10.2. Financial Performance
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic Initiatives